Hormonal
Current clinical-metabolomic biomarkers (including BCAA and lipid profiles) cannot predict individual changes in insulin sensitivity following lifestyle interventions, despite their ability to correlate with baseline insulin levels.
Do not rely on current commercial metabolomic tests (like BCAA or detailed lipid panels) to predict whether you will lose weight or improve insulin sensitivity through exercise. These tests may tell you your current risk status, but they cannot tell you how your body will respond to a specific lifestyle change.
Thus, we demonstrate that... none of the clinical-metabolomic biomarkers, validated in cross-sectional data, are suitable for monitoring longitudinally changes in IR status.
Why this rating
Large multi-cohort analysis (n=444) with rigorous Bayesian projective prediction methods.
Source
Biomarkers of Insulin Resistance and Their Performance as Predictors of Treatment Response in Overweight Adults
Robert J. Brogan et al. · The Journal of Clinical Endocrinology & Metabolism · 2025
DOI 10.1210/clinem/dgaf285
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →